December 7, 2015
Patients with prostate cancer are now being treated with minimally invasive, high intensity focused ultrasound (HIFU) therapy, following the October 2015 U.S. Food and Drug Administration (FDA) regulatory authorization for prostate tissue ablation with the Sonablate HIFU device. The leading U.S. HIFU expert, Vituro Health Medical Director Stephen Scionti, M.D., has begun U.S.-based HIFU procedures.
November 30, 2015
Vituro Health CEO Clete Walker shared his insights about the launch of the Birmingham-based company with the Birmingham Business Journal on Nov. 30, 2015.
Vituro Health, Stephen Scionti, M.D., bring precision healthcare and latest prostate cancer treatment options to U.S. patients
November 19, 2015
The presence of prostate cancer can be signaled by an elevated prostate-specific antigen (PSA) level, a test result which can be alarming to any patient and confirmed by a prostate biopsy. Vituro Health, a comprehensive prostate care provider that empowers men during all stages of life, has launched operations to offer complete prostate management services, including minimally-invasive high intensity focused ultrasound (HIFU) therapy. Until now, HIFU has only been available to patients internationally.
Press Tags: PSA.